To understand the kinetics of antitumor immune response, we longitudinally imaged mice with intracranial GBM tumors during anti-PD-1/CTLA-4 therapy (Fig. 4a), tracking tumor growth with bioluminescent imaging. Here, CTLA4 is linked to neoplasm.